pemirolast pemirolast pemirolast (inn) is a mast cell stabilizer used as an anti-allergic drug therapy. it is marketed under the tradenames alegysal and alamast. pemirolastclinical datatrade namesalamastahfs/drugs.commonographroutes ofadministrationoral, ophthalmicatc codenonelegal statuslegal status us: ℞-only in general: ℞ (prescription only) identifiers iupac name 9-methyl-3-(1h-tetrazol-5-yl)-4h-pyridopyrimidin-4-one cas number69372-19-6 ypubchem cid57697iuphar/bps7329drugbankdb00885 nchemspider51990 nunii2c09nv773mkeggd07476 ychemblchembl1201198 ncomptox dashboard (epa)dtxsid1048338 chemical and physical dataformulac10h8n6omolar mass228.215 g·mol−13d model (jsmol)interactive image smiles cc1=cc=cn2c1=nc=c(c2=o)c3=nnn=n3 ny (what is this?) (verify) clinical trials studying treatments for allergic conjunctivitis have found that an ophthalmic solution containing levocabastine with pemirolast potassium may be more effective in alleviating symptoms than levocabastine alone. it has also been studied for the treatment of asthma. pemirolast has appeared as a possible candidate for sars-cov-2 (covid-19) spike protein disruption and interference. such results were ascertained by molecular dynamics calculations executed on the summit supercomputer. by simulating compounds with fda or similar regulatory approval, the authors found 4 interfacial molecules that could potentially disrupt the sars-cov-2 interface with ace-2 receptors, suggesting that such small molecules could mitigate sars-cov-2 infection. the 4 candidate interfacial molecules included pemirolast, isoniazid pyruvate, nitrofurantoin, and eriodictyol.